Clinical studies of hypoxia modification in radiotherapy

Seminars in Radiation Oncology

Volumn 14, Issue 3, 2004, Pages 233-240

  Kaanders, Johannes H A M ^a   Bussink, Johan ^a   Van Der Kogel, Albert J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CARBOGEN; CISPLATIN; CYTOTOXIN; ERYTHROPOIETIN; ETANIDAZOLE; FLUOROURACIL; METRONIDAZOLE; MISONIDAZOLE; NICOTINAMIDE; NIMORAZOLE; NITROIMIDAZOLE; OXYGEN; PIMONIDAZOLE; RADIOSENSITIZING AGENT; TIRAPAZAMINE;

CANCER RADIOTHERAPY; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; GASTROINTESTINAL DISEASE; HUMAN; HYPERBARIC OXYGEN; HYPOXIA; META ANALYSIS; NEUROPATHY; ONCOLOGY; OUTPATIENT DEPARTMENT; OXYGENATION; PREDICTION; PRIORITY JOURNAL; REVIEW; SCALE UP; TOXICITY; TUMOR; VALIDATION PROCESS;

EID: 3142510861     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2004.04.002     Document Type: Article

References (45)

1. Gray L.H., Conger A.D., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 26:1953;638-648
2. Dische S. Hyperbaric oxygen The Medical Research Council trials and their clinical significance. Br J Radiol. 51:1978;888-894
3. Urtasun R., Band P., Chapman J.D., et al. Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med. 294:1976;1364-1367
4. Dische S. Chemical sensitizers for hypoxic cells A decade of experience in clinical radiotherapy. Radiother Oncol. 3:1985;97-115
5. Dische S., Machin D., Chassagne D. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix An interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol. 26:1993;93-103
6. Eschwege F., Sancho-Garnier H., Chassagne D., et al. Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. Int J Radiat Oncol Biol Phys. 39:1997;275-281
7. Lee D.J., Cosmatos D., Marcial V.A., et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys. 32:1995;567-576
8. Overgaard J., Sand Hansen H., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 46:1998;135-146
9. Overgaard J., Sand Hansen H., Andersen A.P., et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of the larynx and pharynx Report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys. 16:1989;1065-1068
10. Overgaard J., Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 6:1996;10-21
11. Horsman M.R., Overgaard J. Overcoming tumour radioresistance resulting from hypoxia. Steel G.G. Basic Clinical Radiobiology. 2002;169-181 Arnold, London
12. Wang J., Biedermann K.A., Brown J.M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 52:1992;4473-4477
13. Brown J.M., Lemmon M.J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 50:1990;7745-7749
14. Dorie M.J., Brown J.M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 53:1993;4633-4636
15. Horst K.C., Su C.K., Budenz S., et al. Quality-of-life assessment in a phase II randomized trial of tirapazamine in advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 57:(suppl):2003;S223-S224. (abstr)
16. Von Pawel J., von Roemling R., Gatzemeier U., et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol. 18:2000;1351-1359
17. Rojas A., Hirst V.K., Calvert A.S., et al. Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy. Int J Radiat Oncol Biol Phys. 34:1996;357-365
18. Kaanders J.H.A.M., Bussink J., van der Kogel A.J. ARCON A novel biology-based approach in radiotherapy. Lancet Oncol. 3:2002;728-737
19. Kaanders J.H.A.M., Pop L.A.M., Marres H.A.M., et al. ARCON experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 52:2002;769-778
20. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys. 29:1994;427-431
21. Bernsen H.J., Rijken P.F., Peters H., et al. Hypoxia in a human intracerebral glioma model. J Neurosurg. 93:2000;449-454
22. Miralbell R., Mornex F., Greiner R., et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme Report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol. 17:1999;3143-3149
23. Wykoff C.C., Beasley N.J.P., Watson P.H., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60:2000;7075-7083
24. Jones A., Fujiyama C., Blanche C., et al. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin Cancer Res. 7:2001;1263-1272
25. Hoskin P.J., Saunders M.I., Dische S. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer. 86:1999;1322-1328
26. Fyles A., Milosevic M., Hedley D., et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 20:2002;680-687
27. Aquino-Parsons C., Green A., Minchinton A.I. Oxygen tension in primary gynaecological tumours The influence of carbon dioxide concentration. Radiother Oncol. 57:2000;45-51
28. Dische S. Radiotherapy and anaemia - The clinical experience. Radiother Oncol. 20:(suppl):1991;35-40
29. Grau C., Overgaard J. Significance of hemoglobin concentration for treatment outcome. Molls M., Vaupel P. Blood Perfusion and Microenvironment of Human Tumors. 1998;101-112 Springer, Berlin
30. Hirst D.G. What is the importance of anaemia in radiotherapy? The value of animal studies. Radiother Oncol. 20:(suppl):1991;29-33
31. Lutterbach J., Guttenberger R. Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int J Radiat Oncol Biol Phys. 48:2000;1345-1350
32. Blackwell K.L., Kirkpatrick J.P., Snyder S.A., et al. Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effect on hemoglobin. Cancer Res. 63:2003;6162-6165
33. Acs G., Acs P., Beckwith S.M., et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 61:2001;3561-3565
34. Arcasoy M.O., Amin K., Karayal A.F., et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest. 82:2002;911-918
35. Yasuda Y., Fujita Y., Matsuo T., et al. erythropoietin regulates tumour growth of human malignancies. Carcinogenesis. 24:2003;1021-1029
36. Arcasoy M.O., Jiang X., Haroon Z.A. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun. 307:2003;999-1007
37. Leyland-Jones B. BEST Investigators and Study Group, Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 4:2003;459-460
38. Henke M., Laszig R., Rübe C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy Randomised, double-blind, placebo-controlled trial. Lancet. 362:2003;1255-1260
39. Kaanders J.H.A.M., van der Kogel A.J. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet. 363:2004;78-79
40. Littlewood T.J., Bajetta E., Nortier J.W., et al. Effects of epoietin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 19:2001;2865-2874
41. Antonadou D., Cardamakis E., Puglisi M., et al. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies Final results of a randomized phase III study. Eur J Cancer. 37:(suppl 6):2001;144. (abstr)
42. Kaanders J.H.A.M., Wijffels K.I., Marres H.A.M., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 62:2002;7066-7074
43. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:2003;721-732
44. Lee C.-G., Heijn M., di Tomaso E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:2000;5565-5570
45. Delmas C., End D., Rochaix P., et al. The farnesyltransferase inhibitor R11577 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin Cancer Res. 9:2003;6062-6068